CareDx Inc
NASDAQ:CDNA

Watchlist Manager
CareDx Inc Logo
CareDx Inc
NASDAQ:CDNA
Watchlist
Price: 18.9 USD 0.48% Market Closed
Market Cap: 972m USD

CareDx Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

CareDx Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
CareDx Inc
NASDAQ:CDNA
Cash from Operating Activities
$42.6m
CAGR 3-Years
N/A
CAGR 5-Years
11%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

CareDx Inc
Glance View

CareDx Inc. is a vibrant player in the biotech landscape, navigating the intricate world of transplant medicine with a unique focus on precision diagnostics. Founded in 1998 and headquartered in South San Francisco, CareDx is deeply entrenched in the development of solutions that enhance the longevity and quality of life for organ transplant recipients. Their flagship offerings, such as AlloMap and AlloSure, are non-invasive, blood-based tests that provide critical insights into the functioning and health of transplanted organs. These tests are pivotal in assessing transplant recipients for possible organ rejection, thus presenting rapid, reliable data that may preempt irreversible damage. CareDx captures value by providing these sophisticated diagnostic tests and services to transplant centers that require cutting-edge technology to improve patient outcomes. Revenue generation for CareDx is anchored in its comprehensive commercial approach, developing partnerships with healthcare providers and transplant centers globally. By leveraging an innovative mixture of proprietary testing technology and patient-centric solutions, the company taps into the ongoing demand for improved post-transplant care. Their business model primarily revolves around offering subscription-based services that incorporate longitudinal patient monitoring and data analytics—providing healthcare professionals with a steady flow of actionable insights. CareDx further extends its revenue streams through patient management solutions and digital health offerings, enhancing its footprint in the growing transplant diagnostics market. Beyond diagnostics, CareDx's strategic aspirations see it expanding its portfolio into more integrated healthcare solutions, resonating with healthcare practitioners seeking more personalized and predictive transplant care.

CDNA Intrinsic Value
20.44 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is CareDx Inc's Cash from Operating Activities?
Cash from Operating Activities
42.6m USD

Based on the financial report for Sep 30, 2025, CareDx Inc's Cash from Operating Activities amounts to 42.6m USD.

What is CareDx Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
11%

Over the last year, the Cash from Operating Activities growth was 447%.

Back to Top